2026年7月7日，江苏荃信生物医药股份有限公司（荃信生物-B，02509）发布翌日报表公告，披露于当日通过香港联交所场内回购普通股（H股）8,000股，占回购前已发行股本约0.0036%。每股回购价为15.70港元，涉资约12.56万港元。
回购完成后，公司已发行股份（不含库存股份）数目变动为223,373,800股，库存股份数目增至3,697,800股，已发行股本总数维持227,071,600股。
购回授权于2026年5月29日获得通过，授权可购回股份总数为22,436,340股。截至本次回购后，公司累计根据该授权购回股份数量为989,600股，占授权获通过当日已发行股本总数的0.4411%。
公司方面确认已遵守香港联合交易所有限公司证券上市规则的相关规定。本次公告由董事会秘书和联席公司秘书胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.